Viral‐specific T cells for Cytomegalovirus retinitis following hematopoietic stem cell transplantation: A success story

Abstract

AbstractCytomegalovirus retinitis (CMVR) following hematopoietic stem cell transplantation (HCT) for a primary immunodeficiency is a rare but highly morbid condition with potential irreversible consequences despite optimal antiviral pharmacotherapy. Viral‐specific T cells (VSTs) pose a promising and safe approach eradicating intractable viral disease. We describe the case of a 21‐month‐old male with Wiskott–Aldrich syndrome (WAS) and CMVR post HCT with sustained long‐term virologic and clinical response after CMV‐specific T‐cell therapy. This case highlights the need to consider VST as an adjunct upfront strategy in refractory CMVR and for routine ophthalmologic screening and surveillance in high‐risk patients post HCT.